Welcome to our dedicated page for Scholar Rock Holding news (Ticker: SRRK), a resource for investors and traders seeking the latest updates and insights on Scholar Rock Holding stock.
Scholar Rock Holding Corporation (SRRK) is a clinical-stage biopharmaceutical company pioneering targeted therapies that modulate growth factor activation in serious diseases. This page serves as the definitive source for official updates, including clinical trial progress, regulatory milestones, and strategic partnerships.
Investors and researchers will find curated news spanning SRRK's neuromuscular, oncology, and metabolic disorder pipelines. Content includes earnings reports, scientific presentations, and manufacturing updates—all essential for tracking the company's novel niche modulator platform.
Key focus areas include apitegromab in spinal muscular atrophy, obesity therapeutics, and fibrosis interventions. Updates are organized chronologically with clear sourcing to maintain transparency. Bookmark this page for streamlined access to SRRK's advancements in precision biologics.
Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company, announced its participation in several upcoming investor conferences in June. The events include: UBS Obesity Therapeutics Day on May 23 at 9:00 a.m. ET, Jefferies Global Healthcare Conference on June 6 at 2:00 p.m. ET in New York City, and the 45th Annual Goldman Sachs Global Healthcare Conference on June 13 at 9:20 a.m. ET in Miami, Florida. These conferences will feature various presentations and virtual chats, with live webcasts available on Scholar Rock's website and archived for replay for approximately 90 days.
Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company, has announced inducement equity awards under Nasdaq Listing Rule 5635(c)(4).
The awards cover an aggregate of 102,150 shares, including 58,370 stock options and 43,780 restricted stock units. These grants are part of Scholar Rock's 2022 Inducement Equity Plan, aimed at attracting new talent.
The stock options have an exercise price of $13.64, with vesting schedules based on employee service. This news is part of Scholar Rock's ongoing efforts to advance treatments for serious diseases.
Scholar Rock (NASDAQ: SRRK) will host an Investor Day on May 22, 2024, starting at 8:30 a.m. ET in New York City. The event will feature presentations from the executive management team on their myostatin inhibition programs targeting spinal muscular atrophy (SMA) and obesity. Renowned experts Dr. Ania Jastreboff of Yale School of Medicine and Dr. Diana Castro of the Neurology & Neuromuscular Care Center will also provide insights. Participants can access a live webcast and slide presentation via Scholar Rock's website, with a replay available for 90 days.
Scholar Rock, a late-stage biopharmaceutical company focused on innovative treatments for SMA and cardiometabolic disorders, reported Q1 2024 financial results. They are on track to report Phase 3 SAPPHIRE trial data in Q4 2024. Initiating Phase 2 trial for apitegromab in obesity. Strong financial position with $238 million in cash. Positive clinical data presentations for SRK-181 and SRK-439.
FAQ
What is the current stock price of Scholar Rock Holding (SRRK)?
What is the market cap of Scholar Rock Holding (SRRK)?
